On January 16, 2026, the U.S. Supreme Court announced its intent to hear the case of Hikma v. Amarin. This case follows the landmark GSK v. Teva ...

As a result, the FTSE 250-listing expects full-year adjusted pre-tax profit to be no less than £270 million, “comfortably ...

Innovation aims to streamline research journey, positioning the university as a leader in ethical AI-driven scientific ...

Key Takeaways Supreme Court to decide if “generic version” marketing can support induced infringement claims. On Jan. 16, ...

Hikma Pharmaceuticals PLC HIK shares shed 1.73% to £15.38 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.03% to ...

Said Darwazah, Hikma’s executive chairman and former CEO, will assume all CEO responsibilities. Victoria Hull, Hikma’s senior independent director said, “The Board is confident in Hikma’s future ...

The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results between individual stocks. At this point some shareholders may be questioning ...

(Alliance News) - Hikma Pharmaceuticals PLC said Riad Mishlawi is stepping down as chief executive officer on Monday "by mutual agreement", with the company's executive chair and former CEO taking ...

Hikma is introducing the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name Tyzavan. “The approval of Tyzavan underscores our team’s exceptional R&D ...

Hikma Pharmaceuticals ( (GB:HIK)) has shared an update. Hikma Pharmaceuticals PLC announced a significant transaction involving the purchase of ordinary shares by Said Darwazah, the Executive Chairman ...